Shanghai Hile Bio-tech Market Cap ($282.05 Million)
Market Cap & Net Worth: Shanghai Hile Bio-tech (603718)
Shanghai Hile Bio-tech market cap. Shanghai Hile Bio-tech (SHG:603718) has a market capitalization of $282.05 Million (CN¥1.93 Billion) as of November 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #14818 globally and #4351 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Hile Bio-tech's stock price CN¥2.97 by its total outstanding shares 648979700 (648.98 Million). Also see Shanghai Hile Bio-tech cash conversion from operations for how efficiently the company converts equity into cash flow.
Shanghai Hile Bio-tech Market Cap History (2015–2026)
Shanghai Hile Bio-tech market cap history from 2015 to 2026. Data shows change from $2.08 Billion to $282.05 Million (-14.52% CAGR). Check Shanghai Hile Bio-tech (603718) stock price for real-time trading data and today's change.
Shanghai Hile Bio-tech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Hile Bio-tech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Shanghai Hile Bio-tech growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.08x
Shanghai Hile Bio-tech's market cap is 3.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.67 Billion | $343.34 Million | $85.54 Million | 4.86x | 19.51x |
| 2017 | $1.04 Billion | $303.65 Million | $113.74 Million | 3.41x | 9.11x |
| 2018 | $1.19 Billion | $254.57 Million | $21.30 Million | 4.69x | 56.04x |
| 2019 | $1.21 Billion | $277.99 Million | $12.15 Million | 4.34x | 99.39x |
| 2020 | $1.19 Billion | $259.13 Million | $8.93 Million | 4.59x | 133.31x |
| 2021 | $1.44 Billion | $347.29 Million | $53.86 Million | 4.16x | 26.82x |
| 2022 | $926.96 Million | $299.99 Million | $121.61 Million | 3.09x | 7.62x |
| 2023 | $1.02 Billion | $240.72 Million | $62.87 Million | 4.23x | 16.18x |
| 2024 | $656.22 Million | $271.04 Million | $171.18 Million | 2.42x | 3.83x |
| 2025 | $579.29 Million | $187.87 Million | -$311.44 Million | 3.08x | N/A |
Competitor Companies of 603718 by Market Capitalization
Companies near Shanghai Hile Bio-tech in the global market cap rankings as of November 4, 2026. Also see 603718 total asset value for a full breakdown of the balance sheet.
Key companies related to Shanghai Hile Bio-tech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Shanghai Hile Bio-tech (2015–2026)
Market capitalization of Shanghai Hile Bio-tech from 2015 to today. Between 2015 and today, Shanghai Hile Bio-tech's market cap moved from $2.08 Billion to $ 282.05 Million, with a yearly change of -14.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥282.05 Million | -51.31% |
| 2025 | CN¥579.29 Million | -11.72% |
| 2024 | CN¥656.22 Million | -35.48% |
| 2023 | CN¥1.02 Billion | +9.72% |
| 2022 | CN¥926.96 Million | -35.82% |
| 2021 | CN¥1.44 Billion | +21.37% |
| 2020 | CN¥1.19 Billion | -1.47% |
| 2019 | CN¥1.21 Billion | +1.18% |
| 2018 | CN¥1.19 Billion | +15.14% |
| 2017 | CN¥1.04 Billion | -37.87% |
| 2016 | CN¥1.67 Billion | -19.93% |
| 2015 | CN¥2.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Shanghai Hile Bio-tech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $282.05 Million USD |
| MoneyControl | $282.05 Million USD |
| MarketWatch | $282.05 Million USD |
| marketcap.company | $282.05 Million USD |
| Reuters | $282.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The company offers biochemistry reagents, immunoturbidimetric latex reagents, immune turbidimetry reagents, latex enhanced … Read more